| Healthcare and Medical Technology |
1 |
1 |
| Lysosomal Storage Disease |
0 |
0.91 |
| Glycogen Storage Disease (GSD) Type II |
0 |
0.59 |
| California |
0 |
0.42 |
| Child |
0 |
0.42 |
| Pregnancy |
0 |
0.99 |
| Hospital |
0 |
0.34 |
| Birth |
0 |
0.25 |
| Clinical Research |
0 |
0.25 |
| Newborn Screening |
0 |
0.24 |
| COVID-19 |
0 |
0.23 |
| Genomic Medicine |
0 |
0.19 |
| Newborn |
0 |
0.17 |
| Mucopolysaccharidosis Type IS |
0 |
0.12 |
| Biologic Therapy |
0 |
0.09 |
| Gaucher Disease |
0 |
0.09 |
| Genetics |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Heart |
0 |
0.09 |
| Mucopolysaccharidosis |
0 |
0.09 |
| Postpartum |
0 |
0.09 |
| Precision Medicine |
0 |
0.09 |
| Stem Cell Research and Therapy |
0 |
0.09 |
| Travel Medicine |
0 |
0.09 |
| Umbilical |
0 |
0.09 |
| Vein |
0 |
0.09 |